Home › Companies › SMMT

Summit Therapeutics

SMMT Lead: Phase 3 9 Biotech Distilled articles ↓

Oncology Protein

Most recent annual filing: 2026-02-15

Pipeline (3 active programs)

ivonescimab

SMT112 · AK112

Protein Target: PD-1, VEGF-A, VEGF

Non-Small Cell Lung Cancer Phase 3 Akeso
Colorectal Cancer Phase 3 Akeso

ivonescimab

Protein Target: PD-1, VEGF-A

Head and Neck Squamous Cell Carcinoma Phase 3 Akeso

Biotech Distilled coverage (9)

2026-06-11 UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled
2026-06-09 UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch
2026-06-03 UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light
2026-06-02 UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn’t. 🔒 Paid
2026-05-02 UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 🔒 Paid
2026-05-01 UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot 🔒 Paid
2026-03-29 UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data 🔒 Paid
2026-03-01 UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update 🔒 Paid
2026-02-20 Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.